Ahjin Lim

Dear Editor, EGFR (epidermal growth factor receptor)-targeted therapies, which utilize small molecule inhibitors such as erlotinib and osimertinib to inhibit aberrantly activated EGF receptors caused by oncogenic mutations such as L858R and exon 19 deletion occurring primarily in the region coding its kinase domain, have demonstrated significant clinical efficacy in various cancers, particularly non-small cell lung cancer (NSCLC).1 Nevertheless, a substantial challenge to the long-term...